Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Mohs Surgeons' Postoperative Care Practices for Secondary Intention Healing: A National Survey.","authors":"Vixey Silva, Lisa Fronek, Travis Blalock, Emily Coughlin","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This paper seeks to characterize Mohs surgeons' postoperative wound care practices for secondary intention healing (SIH) and identify trends in the use of topical agents and perceived clinical outcomes.</p><p><strong>Methods: </strong>A survey was distributed to American College of Mohs Surgery (ACMS) members to assess demographics, practice settings, wound care preferences, and self-reported outcomes related to SIH. Fisher's exact and χ² tests were used to evaluate associations between surgeon characteristics and wound care practices.</p><p><strong>Results: </strong>Petroleum emollients were used by 96.4% of respondents. Topical antibiotics, most commonly mupirocin and gentamicin, were routinely recommended by 36.1% and were associated with higher reported infection rates (<i>P</i>=0.034). Antiseptic solutions, particularly dilute acetic acid, were more often used by early-career surgeons (<i>P</i>=0.016). Only 10.8% of respondents used topical timolol. Conventional nonadherent dressings were preferred by 91.6% of respondents. Most surgeons reported complete healing within 4 to 8 weeks (72.3%), 95.2% of surgeons indicated infection rates of 5% or less, and 95.2% reported good to excellent cosmetic outcomes.</p><p><strong>Limitations: </strong>Low response rate and self-reported data limited generalizability. Wound location data were not stratified.</p><p><strong>Conclusion: </strong>Postoperative care practices for SIH vary considerably among Mohs surgeons. Despite supporting literature, the use of advanced dressings, antiseptics, and topical timolol remains limited. These findings highlight opportunities for further research and standardization of SIH wound care.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"42-46"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multicenter Trial Evaluating the Safety and Efficacy of a Serum Containing Plant Adaptogens in Patients With Mild-to-Moderate, Persistent Centrofacial Erythema Associated With Rosacea.","authors":"Zoe Diana Draelos, Jacqueline Watchmaker, Diane B Nelson","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Persistent facial erythema is one of the most common subtypes of rosacea, often prompting patients to seek treatment. Characterized by multiple factors including adaptive immune and vascular dysregulation, genetics, and environmental influences, skincare measures aimed at reducing erythema and strengthening the skin barrier are fundamental to treatment. Plant adaptogens are rich phytochemicals that promote homeostasis, helping to increase resistance to stress, mitigate inflammation, support the skin barrier, and prevent premature aging. A serum containing plant adaptogens demonstrated significant improvements from baseline in global skin quality in subjects with mild-to-severe facial photodamage over 12 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;We sought to evaluate the safety and efficacy of a serum containing plant adaptogens (MYS) in subjects with mild-to-moderate persistent centrofacial erythema.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A multicenter, open-label trial enrolled male or female subjects 30 to 65 years of age with mild (2) to moderate (3) persistent centrofacial erythema based on a Modified Clinical Erythema grading scale (M-CEA; 0=clear to 4=severe). A subset of subjects enrolled was taking oral or topical medications for rosacea (≥6 months) with breakthrough erythema. Subjects with &gt;5 papules or pustules were excluded from participation. The investigators assessed erythema based on the M-CEA scale and global inflammatory lesions utilizing a 5-point grading scale (0=none to 4=severe) at baseline, 2, 4, 8, and 12 weeks. Subjects assessed erythema, dryness/flaking, itching, stinging, and burning using a 5-point grading scale (0=none to 4=severe) at baseline, 2, 4, 8, and 12 weeks. Subjects also completed self-assessment questionnaires. Digital photography and adverse events (AEs) were captured throughout the study. In addition to the study product (MYS [AM/PM]), subjects used a standardized skincare regimen that included a gentle cleanser, moisturizer, and sunscreen.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Fifty-five subjects were enrolled and 51 subjects completed the study: 38 in the Non-Medication Treatment Group (N-MTG) and 13 in the Medication Treatment Group (MTG). Significant mean reductions in the appearance of erythema of -17%, -25%, -32%, and -33% were demonstrated from baseline at Weeks 2, 4, 8, and 12 (all &lt;i&gt;P&lt;/i&gt;&lt;0.001), respectively, with each group demonstrating significant reductions over 12 weeks. Subject-assessed erythema demonstrated comparable results for both groups combined, with -22%, -30%, -34%, and -35% significant mean reductions occurring from baseline at Weeks 2, 4, 8, and 12 (all &lt;i&gt;P&lt;/i&gt;&lt;0.001). Significant mean reductions also occurred in papules/pustules at Weeks 4 (-29%), 8 (-43%), and 12 (-58%) (n=34; &lt;i&gt;P&lt;/i&gt;&lt;0.05). Subjects reported improvements in dryness/flaking, itching, stinging, and burning over the study period. After 12 weeks, subjects (94%) reported that flare-ups were not","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"32-37"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pumping Up Dermatologic Drug Reformulation: A Review of How Proton Pump Inhibitors May Revolutionize Scleroderma Treatment.","authors":"Aaron Cheng, David G Cotter, Manisha Ahir, Mohammad A Khan, Mark D Bonnen, Yohannes T Ghebre","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Scleroderma is a rare and often debilitating connective tissue disorder of unknown etiology affecting the skin, lungs, and other visceral organs. Current medical therapies are limited and largely focused on symptoms, particularly in advanced disease. Recent preclinical studies have shown that topically reformulated proton pump inhibitors (PPIs) reduce inflammation and fibrosis, suggesting therapeutic potential in scleroderma. In this article, we explore the emerging role of PPIs as an adjuvant therapy in scleroderma. We also describe the key mechanisms of scleroderma and current therapeutic options and highlight how PPIs modulate molecular pathways central to fibrotic disease.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"38-41"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding Insurance Coverage for Wound Supplies for Patients With Hidradenitis Suppurativa.","authors":"Jordan Bui, Adaora Ntukogu, Jolina T Bui, Nicole A Negbenebor","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lichenoid Drug Eruption From Cetirizine Treated With Upadacitinib and Dupilumab.","authors":"Eingun James Song, Abarajithan Chandrasekaran","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cutaneous lichenoid drug eruptions (LDE) are a group of relatively uncommon adverse drug reactions characterized by widespread erythematous to violaceous scaly papules that can be difficult to differentiate from idiopathic lichen planus. Their increasing prevalence with the use of biologics, tyrosine kinase inhibitors, and immune checkpoint inhibitors has become of particular interest in dermatology. More commonly used medications, including antibiotics, antihypertensives, and nonsteroidal anti-inflammatory drugs, have also been reported to cause LDEs. While the exact pathophysiology of LDE remains to be fully elucidated, certain medications are believed to increase the antigenicity of skin proteins, thereby triggering a T-cell-mediated response via CD8+ cytotoxic T lymphocytes that target basal keratinocytes, while increased interferon γ signaling further amplifies the inflammatory process. Herein, we report a case of LDE induced by an antihistamine (cetirizine) successfully treated with both upadacitinib and dupilumab after failure of systemic corticosteroids.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"47-49"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Dupilumab on Psychological Wellbeing in Moderate-to-Severe Atopic Dermatitis Patients: A Phase IV Clinical Trial.","authors":"Chandler E Johnson, Kareem G Elhage, Riley K Spencer, Joy Q Jin, Samuel Yeroushalmi, Mitchell S Davis, Marwa Hakimi, Wilson Liao, Tina Bhutani","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to prospectively evaluate the emotional impact of dupliumab treatment on patients with atopic dermatitis (AD) using a validated psychometric instrument, the Psychological General Wellbeing (PGWB) index. This index is widely used in nondermatologic conditions and assesses self-representations of intrapersonal affective and emotional states reflecting a sense of subjective wellbeing or distress.</p><p><strong>Methods: </strong>This was a Phase IV, open-label clinical trial using dupilumab for the treatment of moderate-to-severe AD. The primary endpoint was the change in PGWB score at Week 16 of dupilumab treatment compared to baseline.</p><p><strong>Results: </strong>A total of 24 participants completed the study. The change in average PGWB score after 16 weeks of treatment with dupilumab compared to baseline was not statistically significant (5.8±19.7; <i>P</i>=0.15). There was significant improvement in PGWB score at Week 52 of treatment (8.5±17.4; <i>P</i>=0.03). Mean Eczema Area and Severity Index (EASI) improvements at Weeks 16 and 52 were 60.3% and 76.8%, respectively. Regarding Investigator Global Assessment (IGA), 29.2% and 41.7% of participants achieved a score of 0 or 1 at Weeks 16 and 52, respectively.</p><p><strong>Limitations: </strong>This study did not have a control arm and was limited by small sample size.</p><p><strong>Conclusion: </strong>Treatment with dupilumab for 52 weeks was associated with improvement of psychological wellbeing, suggesting that intervention with this interleukin (IL) 4/IL-13 inhibitor is capable of restoring quality of life in these patients.</p><p><strong>Trial administration: </strong>NCT03667014.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"15-19"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the Topical Therapeutic Landscape for Atopic Dermatitis: A Systematic Review.","authors":"Joshua Burshtein, Sara Nahon, Diego Ruiz Dasilva, Graham Litchman","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a common chronic inflammatory disease. Despite its global prevalence, the current standard of care has remained unchanged for many years. Historically, first-line agents include topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs). However, these agents have significant limitations, including local and systemic adverse effects. In the last several years, novel topical therapeutic agents have been approved by the United States Food and Drug Administration (FDA) and more are being developed.</p><p><strong>Objective: </strong>The present review aims to summarize these topical therapeutic advances and report their efficacy and safety relative to the existing armamentarium.</p><p><strong>Methods: </strong>Three searches were conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the Agency for Healthcare Research and Quality Methods Guide for Effectiveness and Comparative Effectiveness Reviews guidelines. These included electronic searches of FDALabel (without date restriction) and PubMed and ClinicalTrials.gov (between April 8, 2020 and April 8, 2025).</p><p><strong>Results: </strong>A total of 52 nongeneric, prescription topical therapeutic agents are currently approved by the FDA for AD, the majority of which are TCS (n=11; 52.4%) and TCIs (n=4; 19.0%). There have been several agents with novel mechanisms of action (n=3; 7.6%) approved by the FDA in recent years, including Janus kinase (JAK) inhibitors, nonsteroidal aryl hydrocarbon receptor (AhR) modulators, and phosphodiesterase 4 (PDE4) inhibitors.</p><p><strong>Conclusion: </strong>In the last 5 years, important innovations in the therapeutic landscape of AD have emerged. Treatments include novel JAK inhibitors, AhR modulators, and PDE4 inhibitors. Adopting these therapies as part of clinical care can improve patients' therapeutic outcomes and quality of life.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 3","pages":"20-30"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147789218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Multiple Miliary Osteoma Cutis Using CO₂ Laser: A Case-Based Exploration.","authors":"Miguel A Aristizabal-Torres, Misty M Hobbs, Thais Pincelli, Olayemi Sokumbi, Alison J Bruce","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Miliary osteoma cutis is an underreported condition that typically presents with firm papules on the face, although involvement of other areas has been described. It commonly presents in middle-aged women with fair skin. Treatment options for this condition are limited. We describe two patients with miliary osteoma cutis, detailing the treatment strategies used, including the successful use of carbon dioxide laser-assisted extraction.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 2","pages":"10-14"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Advancements and Applications of AI-Powered Hair Analysis Tools.","authors":"Tahreem Nawaz, Greg Williams, Jane Yoo","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>We aim to evaluate a subset of artificial intelligence (AI)-powered hair analysis tools and their role in improving diagnostic accuracy, treatment planning, and personalized care in trichology and professional hair care.</p><p><strong>Methods: </strong>A cross-sectional review was conducted using publicly accessible sources, including Google Scholar, company websites, and industry reports. Tools were selected based on professional use, incorporation of AI, and availability of measurable outcomes such as hair density evaluation and treatment monitoring. Devices were categorized by primary function: diagnostic systems, product recommendation platforms, growth monitoring technologies, and surgical planning applications.</p><p><strong>Results: </strong>Ten AI-driven tools were evaluated, each using machine learning or computer vision to assess parameters such as follicle density, scalp condition, and hair thickness. Diagnostic tools provided noninvasive trichoscopic analysis; others enabled personalized product suggestions, tracked treatment outcomes, or supported surgical planning. These technologies automate traditional methods and deliver objective, data-rich insights that can enhance clinical decision-making and user engagement.</p><p><strong>Limitations: </strong>Findings are limited by the scarcity of peer-reviewed validation and reliance on manufacturer-provided data. Many tools lacked comprehensive public documentation, and dataset diversity used in model training was often unspecified, raising concerns about potential algorithmic bias and reduced generalizability.</p><p><strong>Conclusion: </strong>AI-powered hair analysis tools offer transformative potential in trichology by increasing diagnostic precision and enabling tailored treatment strategies. Their broader adoption will require addressing limitations in accessibility, ethical considerations, and dataset inclusivity to ensure equitable and reliable integration into dermatologic and cosmetic practice.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 2","pages":"58-62"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feeding the Skin? Foods in Personal Care Products and the Risk of Allergy.","authors":"Mara O'Connor, Peter Lio","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The interrupted skin barrier seen in atopic dermatitis (AD) increases exposure to environmental antigens including those in food, which contributes to the increased prevalence of food allergies in the AD population. This relationship is further explored in the dual allergen exposure hypothesis, which examines the differences in immune system response between cutaneous and oral exposures. It was previously thought that avoiding early oral exposure would decrease the likelihood of developing food allergy; however, several studies have demonstrated that earlier oral exposure increases tolerance. On the other hand, exposure to food antigens through the skin activates the helper T-cell 2 pathway, which promotes development of allergy. There have also been several studies demonstrating that aggressive treatment of AD decreases the risk of developing food allergies. Based on these findings, there is concern that inclusion of food-based ingredients in personal care products, such as moisturizers that act as main components of AD treatment regimens, may increase the likelihood of developing allergies to the included foods. However, there are many commonly used food-based ingredients that have low rates of allergy, which raises the question of why some antigens are more likely to result in allergic sensitization while many others remain benign.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"19 2","pages":"43-46"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}